MedTrace Logo

Menstrual Blood Stem Cells in Severe Covid-19

NCT05019287 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-09-02

No results posted yet for this study

Summary

In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of menstrual blood stem cells. The improvement in the clinical, laboratory and radiological manifestations will be evaluated in treated patients compared with the control group.

Conditions

  • Covid19
  • Cytokine Storm

Interventions

BIOLOGICAL

Allogeneic human menstrual blood stem cells secretome

This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.

OTHER

Intravenous saline injection

Intravenous saline injection in addition to standard care

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    collaborator OTHER

  • Avicenna Research Institute

    lead OTHER

Principal Investigators

  • Mina Fathi Kazerooni, MD, PhD · Nanobiotechnology Research Center Avicenna Research Institute, ACECR, TEHRAN, IRAN

  • Ali Dehghan-Manshadi, MD · Department of Infectious Diseases and Tropical Medicine - Iranian Research Center for HIV/AIDS,TUMS

  • Samrand Fattah-Ghazi, MD · Tehran University of Medical Science (TUMS)

  • Somaieh Kazemnejad, PhD · Nanobiotechnology Research Center Avicenna Research Institute, ACECR, TEHRAN, IRAN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-17
Primary Completion
2021-05-21
Completion
2021-06-09

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019287 on ClinicalTrials.gov